This site uses cookies. To find out more about cookies and how to manage them please see our Cookie policy.
By using this website you agree to cookies being placed on your device.

Bronchitol AEs were generally mild or moderate and consistent with CF and its treatment1

Respiritory adverse events table
For full list of adverse events, see Bronchitol Summary of Product Characteristics3

  • A productive cough may be considered part of the therapeutic effect4
  • Following bronchodilator use and initiation dose assessment, the incidence of bronchospasm is low4,5
  • No evidence for an increase in growth of microorganisms6-8



1.Bilton D et al. J Cystic Fibrosis 2011, Suppl 20 (A78). 2.Pharmaxis data on file 2 - ae01dbp1_101 – Adverse Events by System Organ Class and Preferred Term. 3.Bronchitol Summary of Product Characteristics (see link below). 4.Bilton D et al. Eur Respir J 2011; 38: 1071-1080. 5.Aitken ML et al. Am J Respir Crit Care Med. 2012; 185(6): 645-652. 6.Jaques A et al. Chest 2008; 133: 1388-96. 7.Teper A et al. Journal of Cystic Fibrosis 2011; 10: 1–8. 8.Bilton D et al. Inhaled dry powder mannitol in Cystic Fibrosis: the microbiology demographics & results from the Phase III studies (CF301 and CF301). Poster: ECFS Hamburg 2011.

Adverse events should be reported to Pharmaxis Ltd by email: adverse.events@pharmaxis.com.au.